Phaseline

Companies › Alpheus Medical

Alpheus Medical: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 2 Phase 1, 2 Phase 2; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
5-ALA HCl–Phase 2Glioblastoma; Glioblastom WHO Grade 4Oct 2027
LIDU ultrasound
Low-intensity, defocused ultrasound device used to activate porphyrin metabolites for tumo
–Phase 1Glioblastom WHO Grade 4Oct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07862647LIDU ultrasoundPhase 1Glioblastom WHO Grade 4OncologyOct 2027
NCT078626475-ALA HClPhase 1Glioblastom WHO Grade 4OncologyOct 2027
NCT072256215-ALA HClPhase 2GlioblastomaOncologyDec 2027
NCT072256215-ALA HClPhase 2GlioblastomaOncologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Norroy Bioscience Beijing Yongtai Ruike Biotechnology Company Tianjin ConjuStar Biologics Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Imbioray (Hangzhou) Biomedicine

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.